Cardiogenic shock is the leading cause of mortality in ... Smith SC Jr, Feldman TE, Hirshfeld JW Jr, et al. ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report ...

The Altshock-2 trial demonstrates no benefit in survival or successful bridge to HRT with early initiation of IABP therapy among patients presenting with SCAI-Cardiogenic Shock Working Group stages ...

A simplified risk stratification model based on the cardiogenic shock (CS) classification system from the Society for Cardiovascular Angiography and Intervention (SCAI) effectively predicts ...

The first clinical guidance for cardiogenic shock will be presented at the American College of Cardiology Scientific Session ...

Compared with standard medical care, early use of a temporary intra-aortic balloon pump (IABP) to support heart function in ...

According to reports, his death was caused by cardiogenic shock as a result of an acute myocardial infarction, or a severe heart attack. The reports further confirmed that the actor has been ...

The full results of the phase III REVERSE-IT trial continue to show that ticagrelor (Brilinta)-reversing therapy bentracimab ...

Compared with standard medical care, early use of a temporary intra-aortic balloon pump (IABP) to support heart function in patients who were critically ill with cardiogenic shock caused by heart ...

(European Heart Journal) In heart failure complicated by cardiogenic shock, early intra-aortic balloon pump (IABP) placement did not help clinical outcomes in the small randomized trial Altshock-2.

"The DanGer Shock RCT results provide the highest level of scientific evidence demonstrating that Impella CP increases survival in patients with cardiogenic shock secondary to STEMI, which led the ...

WASHINGTON—The Society for Cardiovascular Angiography & Interventions (SCAI) has published a first-of-its-kind educational resource for interventional cardiologists and imaging specialists ...